Clinical TrialHighlighted
MHID-1498378PMID: 392581912024Heliyon
Fenglin Wu, Jun Ma, Junli Xue, Xue Jiang, Jinyu Liu, Jiashuo Zhang, et al.
Background: Consumption of hydrogen-rich water (HRW) has been shown to have anti- inflammatory and metabolic-modulatory benefits.
Objective: A randomized, placebo-controlled trial was conducted to assess the potential blood uric acid-lowering effects of HRW consumption with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia.
Methods: The Placebo grou
Observational Study
MHID-8360107PMID: 293215092018Scientific Reports
Masaaki Nakayama, Noritomo Itami, Hodaka Suzuki, Hiromi Hamada, Ryo Yamamoto, Kazumasa Tsunoda, et al.
Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30–80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocate
Observational StudyHighlighted
MHID-9655362PMID: 289029002017PLoS ONE
Masaaki Nakayama, Noritomo Itami, Hodaka Suzuki, Hiromi Hamada, Naoyuki Osaka, Ryo Yamamoto, et al.
Background and aim: It is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H2) is biologically active as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H2 (30 to 80 ppb)-enriched dialysis solution, to co
